EGFR and cancer: On one hand, extensive attention has been paid to the clinical trials on the efficacy among KRAS-mutant cancer patients, and findings indicated that KRAS-mutant patients could hardly benefit from anti-EGFR therapy like panitumumab plus FOLFOX4, highlighting the pressing need for other combination strategies and novel targeted medications (23).